{"organizations": [], "uuid": "39079232fe1a6ef30cfbcd14f4a880e0ebbbf202", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-concert-pharmaceuticals-completes/brief-concert-pharmaceuticals-completes-enrollment-in-phase-2a-trial-of-ctp-543-in-alopecia-areata-idUSASC09X97", "country": "US", "domain_rank": 408, "title": "BRIEF-Concert Pharmaceuticals Completes Enrollment In Phase 2A Trial Of CTP-543 In Alopecia Areata", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-25T14:09:00.000+03:00", "replies_count": 0, "uuid": "39079232fe1a6ef30cfbcd14f4a880e0ebbbf202"}, "author": "", "url": "https://www.reuters.com/article/brief-concert-pharmaceuticals-completes/brief-concert-pharmaceuticals-completes-enrollment-in-phase-2a-trial-of-ctp-543-in-alopecia-areata-idUSASC09X97", "ord_in_thread": 0, "title": "BRIEF-Concert Pharmaceuticals Completes Enrollment In Phase 2A Trial Of CTP-543 In Alopecia Areata", "locations": [], "entities": {"persons": [{"name": "alopecia areata", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "brief-concert pharmaceuticals", "sentiment": "negative"}, {"name": "concert pharmaceuticals inc", "sentiment": "none"}, {"name": "alopecia areata reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 25 (Reuters) - Concert Pharmaceuticals Inc:\n* CONCERT PHARMACEUTICALS COMPLETES ENROLLMENT IN PHASE 2A TRIAL OF CTP-543 IN ALOPECIA AREATA\n* CONCERT PHARMACEUTICALS INC - EXPECTS TO REPORT TOPLINE DATA FROM 4 MG AND 8 MG COHORTS OF PHASE 2A TRIAL IN Q4 OF 2018\n* CONCERT PHARMACEUTICALS INC - PHASE 2B CLINICAL TRIAL EVALUATING CTP-543 IS EXPECTED TO BEGIN IN 2019 Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-04-25T14:09:00.000+03:00", "crawled": "2018-04-25T14:24:48.023+03:00", "highlightTitle": ""}